EARLY DETECTION OF LIVER DISEASE AND CANCER
This group focuses on identification and development of cancer biomarkers to assist early detection and guide therapies. Our work in this area has identified biomarkers in specific proteins, in the DNA fragments in urine, and in the blood stream. One protein, GOLPH 2 GP73, has been studied in thousands of people and is approved by the Chinese FDA equivalent for use in China. It is currently in development by Abbott Labs for use in the U.S. to detect HCC early. This is licensed to a spin out company, Glycotest, which is co-owned by BSBI and the inventors.
Our scientists have also determined that human urine contains small DNA fragments from the blood that come from virtually every organ, and have developed a panel of tests to detect specific cancer associated mutations in DNA isolated from human urine. This is licensed to another spin out company, called JBS.